The distinctive feature of Grape King Bio Hericium erinaceus mycelium raw material lies in its unique active compound Erinacine, which promotes the secretion of Nerve Growth Factor (NGF) and demonstrates significant effects on neurological health and anti-aging. In terms of production technology, through proprietary strain breeding and liquid fermentation technology, Grape King Bio has developed the world's only 40-ton fermentation tank technology, specifically designed to produce mycelium with high concentrations of Erinacine A (>5 mg/g), while also containing active compounds such as Erinacine C and S. Regarding research publications, Grape King has published 38 SCI papers over the past decade, with comprehensive safety studies including various toxicity tests. Additionally, they have completed 3 human clinical trials with 2 more ongoing, and secured 16 patents, demonstrating Grape King Bio leadership position in Hericium erinaceus research and development.
New Dietary Ingredient (NDI) Notification
Halal
Hericium erinaceus mycelium powder
GRAPE KING BIO LTD
H-111880517-00003-9
FSSC22000 GMP HACCP ISO22000
Raw Material Storage Conditions (Temperature, Humidity) Monitored Daily Strain preserved in liquid nitrogen (L-N2), with annual tests for viability and growth rate. 2. Inoculation of seed culture into 100-liter fermentation tanks in an aseptic workbench using Erlenmeyer flasks; bacterial contamination tests are conducted every three months. 3. After controlling the seed culture tank quality using API ZYM, the culture is then transferred to a ton-scale fermentation tank. 4. Fermentation Quality Control Record (Color, Odor, Microscopic Inspection, pH Value, Residual Glucose, Contaminant Bacterial Growth and Culture). 5. Fermentation parameters monitored daily. 6. Freeze-drying and packaging processes adhere to cleanroom standards of Class 100,000 or higher. Thin-film centrifugal vacuum concentration equipment is used at 55°C to concentrate 10 times in one second, reducing thermal damage.
Certificate of Analysis (COA) including active ingredients such as Erinacine A. 2. Globally unique fermentation strain identification report (ITS1 similarity ≥99.5%). 3. Globally unique use of API ZYM for rapid control of microbial contamination. 4. Globally unique, with each batch of fermented powder undergoing outsourced acute toxicity testing (in vivo), and included as part of the product acceptance criteria.
Evaluation of the toxicological safety of erinacine A-enriched Hericium erinaceus in a 28-day oral feeding study in Sprague-Dawley rats. Food Chem Toxicol 70:61-67 2014 2. Genotoxicity profile of erinacine A-enriched Hericium Erinaceus mycelium.Toxicology Reports 1195-1201 2014 3. Protective Effects of Hericium erinaceus Mycelium and Its Isolated Erinacine A against Ischemia-Injury-Induced Neuronal Cell Death via the Inhibition of iNOS/p38. Int. J. Mol. Sci. 15:15073-89 2014 4. Erinacine A-enriched Hericium erinaceus mycelium meliorates Alzheimer’s Disease related pathologiesin APPswe/PS1dE9 transgenic mice. J Biomed Sci 27:49 2016 5. Erinacine S, a Rare Sesterterpene from the Mycelia of Hericium erinaceus. J.Nat.Prod 79:438411 2016 6. Inhibitory effect of Erinacines A on the growth of DLD-1 colorectal cancer cells is induced by generation of reactive oxygen species and activation of p70S6K and p21. J. Funct. Food 21:474484 2016 7. A Comparative Proteomic Analysis of Erinacine A’s Inhibition of Gastric Cancer Cell Viability and Invasiveness. Cell. Physiol. Biochem. 43,195208 2017 8. A proteomics approach to identifying novel protein targets involved in erinacine A-mediated inhibition of colorectal cancer cells' aggressiveness. J Cell Mol Med. 21:588599 2017 9. Lion’s Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes), Modulates Purinoceptor -Coupled Calcium Signaling and Murine Nociceptive Behavior. Int J Med Mushrooms 19:499-507 2017 10. A xanthurenate and an isoindolinone from the mycelia of Hericium erinaceum. Phytochemistry Letters 26:218-221 2018 11. Acute and developmental toxicity assessment of erincine A-enriched Hericium erinaceus mycelia in Sprague-Dawley rats. Drug Chem Toxicol 41:459-464 2018 12. Erinacine A-Enriched Hericium erinaceus Mycelium Produces Antidepressant-Like Effects through Modulating BDNF/PI3K/Akt/GSK-3β Signaling in Mice. Int. J. Mol. Sci. 19.2, 341 2018 13. Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines. Behavioural Neurology 2018 14. The Cyanthin Diterpenoid and Sesterterpene Constituents of Hericium erinaceus Mycelium Ameliorate Alzheimer’s Disease-Related Pathologies in APP/PS1 Transgenic Mice. Int. J. Mol. Sci. 19, 598 2018 15. Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia. Molecules 24.8, 1624 2019 16. Anti-Inflammatory Effect of Erinacine C on NO Production Through Down-Regulation of NF- B and Activation of Nrf2-Mediated HO-1 in BV2 Microglial Cells Treated with LPS. Molecules 24.18, 3317 2019 17. Effect of ethanol extracts of Hericium erinaceus mycelium on morphine‑induced microglial migration. Mol.Med.Rep. 20,52795285 2019 18. Erinacine A-enriched Hericium erinaceus mycelia promotes longevity in Drosophila melanogaster and aged mice. PLoS ONE 14: e0217226 2019 19. Induction Apoptosis of Erinacine A in Human Colorectal Cancer Cells Involving the Expression of TNFR, Fas, and Fas Ligand via the JNK/p300/p50 Signaling Pathway With Histone Acetylation. Front Pharmacol. 15;10:1174 2019 20. Thirteen-Week Oral Toxicity Evaluation of Erinacine A-Enriched Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes), Mycelia in Sprague-Dawley Rats. Int J Med Mushrooms 21:401-404 2019 21. Effects of Hericium erinaceus Mycelium Extracts on the Functional Activity of Purinoceptors and Neuropathic Pain in Mice with L5 Spinal Nerve Ligation. Evid Based Complement Alternat Med. 2020: 2890194，2020 22. Hericium erinaceus enhances neurotrophic factors and prevents cochlear cell apoptosis in senescence accelerated mice. J. Funct. Food 66:103832 2020. 23. Post‐Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease. Antioxidants 9, 137 2020 24. Prevention of Early Alzheimer’s Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Front Aging Neurosci 12:155 2020 25. Hericium erinaceus mycelium and its small bioactive compounds promote oligodendrocyte maturation with an increase in myelin basic protein. Sci Rep. 11:6551 2021 26. Apoptotic mechanisms of gastric cancer cells induced by isolated Erinacine S through epigenetic histone H3 methylation of FasL and TRAIL. Food Funct 12.8,34553468 2021 27. Erinacine A-Enriched Hericium erinaceus Mycelium Delays Progression of Age-Related Cognitive Decline in Senescence Accelerated Mouse Prone 8 (SAMP8) Mice. Nutrients, 13, 3659 2021 28. Preclinical Bioavailability, Tissue Distribution, and Protein Binding Studies of Erinacine A, a Bioactive Compound from Hericium erinaceus Mycelia Using Validated LC-MS/MS Method. Molecules 26.15, 4510 2021 29. Hericium erinaceus mycelium ameliorate anxiety induced by continuous sleep disturbance in vivo BMC Complement. Med Ther 21:295 2021 30. Effects of erinacine A-enriched Hericium erinaceus on elderly hearing-impaired patients: A double-blind, randomized, placebo-controlled clinical trial. J. Funct. Food 97:105220 2022 31. Erinacine A attenuates glutamate transporter 1 downregulation and protects against ischemic brain injury. Life Sci. 2022 306:120833. 2022 32. Hericium erinaceus Mycelium Ameliorates In Vivo Progression of Osteoarthritis. Nutrients 14:2605 2022 33. Identification of Common Liver Metabolites of the Natural Bioactive Compound Erinacine A, Purified from Hericium erinaceus Mycelium. Applied Sciences 12,1201 2022 34. Erinacine S from Hericium erinaceus mycelium promotes neuronal regeneration by inducing neurosteroids accumulation. J Food Drug Anal 31,32 2023 35. Neuroprotective Effects of Erinacine A on an Experimental Model of Traumatic Optic Neuropathy. Int J Mol Sci 24,1504 2023 36. Discovery of a New Compound, Erinacerin W, from the Mycelia of Hericium erinaceus, with Immunomodulatory and Neuroprotective Effects. Molecules 29, 812 2024 37. Erinacine S, a small active component derived from Hericium erinaceus, protects oligodendrocytes and alleviates mood abnormalities in cuprizone-exposed rodents. Biomed Pharmacother.173, 116297 2024 38. The Cerebral Protective Effect of Novel Erinacines from Hericium erinaceus Mycelium on In Vivo Mild Traumatic Brain Injury Animal Model and Primary Mixed Glial Cells via Nrf2-Dependent Pathways. Antioxidants.; 13, 371 2024
Taiwan (R.O.C. Patent No. M491474)
Embedding structure of Hericium erinaceus mycelium with neuroprotective function
Taiwan (R.O.C. Patent No. I516598)
Culture method for preventing rapid degradation of erinacine A produced during fermentation of Hericium erinaceus mycelium
Taiwan (R.O.C. Patent No. I560273)
Hericium erinaceus, active substances of Hericium erinaceus mycelium with pain-reducing efficacy, preparation method thereof, and pharmaceutical composition comprising the same
China (Patent No. ZL 201620459984.4)
Embedded granule comprising Hericium erinaceus mycelium embedding nerve growth factor-promoting lactic acid bacteria
Taiwan (R.O.C. Patent No. I605819)
Active substance for treating dementia, preparation method thereof, pharmaceutical composition comprising the same, and preparation method of the pharmaceutical composition
Japan (Patent No. 6533834)
Active substance for preventing hearing loss, composition comprising the same, and preparation method thereof
United States (U.S. Patent No. 10,405,504)
Active substance for preventing hearing loss, composition comprising the same, and preparation method thereof
China (Patent No. ZL 201580000569.0)
Erinacine, active substances of Hericium erinaceus mycelium with pain-reducing efficacy, preparation method thereof, and pharmaceutical composition comprising the same
Taiwan (R.O.C. Patent No. I595880)
Active substance for preventing hearing loss, preparation method thereof, pharmaceutical composition comprising the same, and preparation method of the pharmaceutical composition
Japan (Patent No. 6757405)
Erinacine, active substances of Hericium erinaceus mycelium with pain-reducing efficacy, preparation method thereof, and pharmaceutical composition comprising the same
China (Patent No. ZL 201610002997.3)
Active substance for treating dementia, composition comprising the same, and preparation method thereof
Japan (Patent No. 6952812)
Use of Hericium erinaceus mycelium extract in preparation of pharmaceutical composition for improving central nervous system myelination
Taiwan (R.O.C. Patent No. I771561)
Use of Hericium erinaceus mycelium extract in preparation of pharmaceutical composition for improving central nervous system myelination
Taiwan (R.O.C. Patent No. I798936)
Use of active substances from Hericium erinaceus mycelium for preventing or treating retinopathy
United States (U.S. Patent No. 11,648,233)
Erinacine, active substances of Hericium erinaceus mycelium with pain-reducing efficacy, preparation method thereof, and pharmaceutical composition comprising the same
China (Patent No. ZL 202111561046.7)
Use of active substances from Hericium erinaceus mycelium for preventing or treating retinopathy
